Stryker shoots for first Chinese acquisition with $764m Trauson offer
This article was originally published in Clinica
Orthopaedic firm Stryker has become the latest medtech player to look East for growth, making a $764 million offer for Chinese trauma and specialist Trauson. The offer, worth HK$7.50 ($0.97) per Trauson share, gives the firm an enterprise value of around $685 million. It also represents a 45% premium over Trauson's share price of HK$5.16 on 8 January, when trading was halted on the Hong Kong Stock Exchange.